Ted Torphy headshot.JPG

Ted Torphy, Chair, Manager
Ted Torphy, Ph.D., is the Chief Scientific Officer of BioMotiv and Chair of the Cystic Fibrosis Foundation Therapeutics, Inc. Dr. Torphy brings over 30 years of experience in the pharmaceutical Industry, including at Johnson & Johnson and SmithKlineBeecham, with a succcessful record in both small-molecule and large-molecule drug discovery.



Baiju R. Shah, Manager
Mr. Shah is Chief Executive Officer of BioMotiv and co-leader of The Harrington Project for Discovery & Development. Prior to BioMotiv, he was President and CEO of BioEnterprise; during Mr. Shah's tenure, the initiative assisted in the creation, recruitment, and acceleration of more than 110 bioscience companies in Cleveland that collectively attracted $1.3 Billion in new funding. He has been named an Ernst & Young Entrepreneur of the Year and has been recognized as one of Cleveland's most influential leaders. He received a J.D. from Harvard Law School and a B.A. from Yale University.


Feroz Papa, Founder                                                                          Feroz Papa, MD, PhD, is a Professor of Medicine at the University of California at San Francisco (UCSF). Dr. Papa completed his MD and PhD (in biochemistry) degrees at the University of Chicago, followed by postgraduate clinical training in internal medicine and endocrinology and a postdoctoral fellowship, at UCSF. Dr. Papa is a member of the UCSF Diabetes Center and the California Institute for Quantitative Biosciences. Over the last decade, his lab has been studying the fundamental biology—and small molecule modulation—of the IRE1 life-death switch. He is a recipient of the Charles E. Culpeper Scholar Award, a Career Award in the Biomedical Sciences from the Burroughs Wellcome Fund, and the National Institutes of Health (NIH) Director’s New Innovator Award (DP2). He has been inducted into the American Society of Clinical Investigation (ASCI), was selected as a Harrington Discovery Institute Scholar Innovator, and has been elected to the Association of American Physicians (AAP). 


Mark Chin, Board Member
Mark Chin is an Investment Manager at Arix Bioscience, an investment firm focused on the biotechnology space.  Mark was previously a Principal at Longitude Capital, where he focused on investments in private and public biotechnology and medical technology companies.  Prior to Longitude, he was a Consultant at the Boston Consulting Group, where he was responsible for strategy and corporate development projects for pharmaceutical and biotechnology companies.  Prior to BCG, Mark worked in Corporate Development at Gilead Sciences and Market Planning at Genentech.  Mark has a MBA from The Wharton School at the University of Pennsylvania, a MS in Biotechnology from the University of Pennsylvania, and a BS in Management Science from the University of California at San Diego.